Telo Genomics Corp.
Telo Genomics Corp.
Your view on TDSGF
Overview
What the company does, where it operates, and who runs it.
About Telo Genomics Corp.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Sabine Mai
- Headquarters
- MaRS Centre, Toronto, ON, CA
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Sabine Mai
- Headquarters
- MaRS Centre, Toronto, ON, CA
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions.
It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases.
The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres.
The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma.
The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Telo Genomics Corp., and the rating behind it. TDSGF last traded at $0.04; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Telo Genomics Corp.. Starting points for Telo Genomics Corp.: EPS -$0.02, beta 0.04 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Telo Genomics Corp.. Telo Genomics Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Telo Genomics Corp.. Trailing twelve-month EPS for Telo Genomics Corp. stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Telo Genomics Corp.. Telo Genomics Corp. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Telo Genomics Corp. valued side by side against its closest peers. Telo Genomics Corp. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Telo Genomics Corp., and how their positions are changing. At a $3.8M market value, institutional positions materially move Telo Genomics Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Telo Genomics Corp. executives and directors. Shares of Telo Genomics Corp. have traded between $0.03 and $0.09 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Telo Genomics Corp.. Telo Genomics Corp. is a $3.8M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Telo Genomics Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Telo Genomics Corp.. Coverage tracks Telo Genomics Corp. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.